Program
garsorasib
Also written as “D-1553”, “IN10018 in combination with D-1553” and “D-1553 Tablet”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung, led by 3 companies.
Drug pageGarsorasib: every studyAll 11 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| InventisBioits history only | 62 open or running | phase 2since Sep 27, 2020 | Sep 27, 2020 | Dec 31, 2027phase 2 · NCT05379946 |
| InxMed (Shanghai) | 11 open or running | phase 3since Aug 29, 2025 | Aug 29, 2025 | Sep 2028phase 3 · NCT07174908 |
| Sino Biopharmaceuticalits history only | 11 open or running | phase 3since Mar 3, 2024 | Mar 3, 2024 | none ahead |
Also a collaborator on its studies: Merck.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of InxMed (Shanghai) only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Jan 25, 2022Named garsorasibINNProposed as its International Nonproprietary Name in WHO's List 126 · before, D-1553
- Aug 29, 2025First study: phase 3 study in Carcinoma, Non-Small-Cell LungFirst studyNCT07174908 · 400 planned · China
Ahead
- Sep 2028Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungNCT07174908
TargetBeta
“An orally available inhibitor of the oncogenic KRAS substitution mutation, G12C, ”NCIt, by rule
Other programs on KRAS
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| sotorasibrule | Amgen | phase 3 | 28 |
| adagrasibrule | Bristol-Myers Squibb | phase 3 | 16 |
| olomorasib | Eli Lilly | phase 3 | 16 |
| divarasib | Hoffmann-La Roche | phase 3 | 13 |
| KRAS G12D Inhibitor VS-7375rule | Genfleet Therapeutics (Shanghai) | phase 3 | 12 |
| glecirasibrule | Allist Pharmaceuticals | phase 3 | 12 |
| calderasib | Merck | phase 3 | 12 |
| daraxonrasibrule | Revolution Medicines | phase 3 | 10 |
| KRAS G12D Inhibitor HRS-4642 | Jiangsu HengRui Medicine | phase 3 | 7 |
| zoldonrasibrule | Revolution Medicines | phase 3 | 6 |
| HRS-7058 | Jiangsu HengRui Medicine | phase 3 | 6 |
| opnurasibrule | Novartis | phase 3 | 5 |
Studies
The one study InxMed (Shanghai) leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07174908Carcinoma, Non-Small-Cell Lung · China | 3 | Recruiting | Sep 2028 | 400 |
How it is read
Names in the registry
- “D-1553”, 5 entries
- “IN10018 in combination with D-1553”, 1 entry
- “D-1553 Tablet”, 1 entry
- “[14C] D-1553”, 1 entry
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.